NovoCure Ltd Dossier - Source-backed chat

NovoCure Ltd

NVCRNASDAQ

SectorHealth Care

IndustryMedical Devices

Beta (adjusted)0.99

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $15.92Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1.9B

Enterprise Value $2B

Shares Outstanding 115.6M diluted

Moat Rating None

Next Earnings Date25 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

NovoCure is transitioning into a multi-indication oncology platform utilizing its proprietary Tumor Treating Fields (TTFields) therapy. While the company achieved strong double-digit revenue growth in Q1 2026 driven by European expansion and early momentum from the Optune Pax launch, the recent Phase 3 TRIDENT trial failed to meet its primary endpoint of overall survival in newly diagnosed glioblastoma. This clinical setback limits near-term upside from earlier TTFields integration, though the safety and feasibility of concurrent use were confirmed. With mounting net losses ($71.1 million in Q1 2026) and a high cost structure, the stock is a Hold pending clearer visibility on commercial execution for Optune Pax and upcoming regulatory decisions.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$17.00

Mean target$27.14

High · most bullish analyst$52.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Optune Pax adoption is constrained by slow reimbursement timelines and modest survival benefits, while the core GBM franchise faces pricing pressures. Continued high R&D and SG&A expenses widen net losses, leading to further erosion of shareholders' equity and potential capital dilution.

Base CaseCentral scenario

The core glioblastoma business maintains stable mid-single-digit growth, while the commercial launches of Optune Pax and Optune Lua contribute $15 million to $25 million in collective revenue for FY 2026. Gross margins remain stable in the mid-70s, and the company achieves its updated FY 2026 revenue guidance of $690 million to $710 million. Adjusted EBITDA approaches breakeven by year-end as launch costs normalize.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong Q1 2026 financial performance with net revenues up 12% YoY to $174.1 million, beating consensus estimates.
Rapid early adoption of Optune Pax with 169 prescriptions and 90 patient starts within seven weeks of FDA approval.
Secured first major commercial payer coverage for Optune Pax from Elevance Health, covering 30 million lives.
Robust balance sheet with $432.0 million in cash, cash equivalents, and short-term investments as of March 31, 2026.

Key Investment Risks

Phase 3 TRIDENT trial failed to meet its primary endpoint of demonstrating a statistically significant improvement in overall survival.
Widening net losses, reaching $71.1 million in Q1 2026 compared to $34.3 million in Q1 2025.
Erosion of shareholders' equity, which declined to $330.7 million as of March 31, 2026, from $340.5 million at the end of 2025.
High non-cash share-based compensation expenses ($43 million in Q1 2026) impacting GAAP profitability.

Thesis Invalidation Triggers

Slower-than-expected commercial uptake or reimbursement delays for Optune Pax.
Failure to secure FDA approval for the brain metastases indication in Q4 2026.
Significant delays in fully enrolling the Phase 3 KEYNOTE D58 clinical trial by the end of 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.